The World Health Organization (WHO) has launched an AI tool in beta to help policymakers, experts and healthcare professionals access sexual and reproductive health information faster.

Called ChatHRP, the tool was created by WHO’s Human Reproduction Programme and draws only on verified research and guidance collected by HRP and WHO.

It uses natural language processing and retrieval-augmented generation to produce referenced content and cut the time spent searching through documents across different platforms and databases.

WHO said ChatHRP also has multilingual capabilities and low-bandwidth functionality to support use in a wide range of settings.

The beta-testing phase is aimed at a broad professional audience, including policymakers, healthcare workers, researchers and civil society groups.

WHO said the tool can help users quickly access up-to-date evidence, find sources for academic work and verify information on sexual and reproductive health and rights.

Examples of questions it can answer include the latest violence against women data in Oceania for women aged 15 to 49, recommendations on managing diabetes during pregnancy, and whether PrEP and contraception can be used at the same time. PrEP is medicine used to reduce the risk of getting HIV.

WHO added that the system will be updated regularly as new HRP materials are published and includes a feedback loop so users can flag gaps in the information provided.

The launch comes amid wider concern about misinformation in sexual and reproductive health.

A 2025 scoping review found that misinformation in digital spaces is a systemic issue that can undermine human rights, reinforce discriminatory social norms and exclude marginalised voices.

The review also said misinformation can affect health systems by shaping provider knowledge and practice, disrupting service delivery and creating barriers to equitable care.

WHO said ChatHRP is intended to give users streamlined access to reliable information as a counter to “algorithms, opinions, or misinformation”.

Women’s HealthX has announced its lineup of healthcare trailblazers speaking on Chronic Disease Management, alongside other specialisations including Fertility, Sexual Health, Maternity, Menopause and Cognitive Health, taking a holistic approach to women’s health.

It will bring together 750+ leaders across pharma, health systems, and innovation to address one of the most urgent and underexamined challenges in healthcare; the sex difference gap in data and evidence.

Since cardiovascular disease remains the leading cause of death among women globally, and autoimmune and neurological conditions affect women at significantly higher rates, Women’s HealthX will home in on chronic disease management with 17+ sessions spotlighting case studies and lessons learned.

The Chronic Disease Management Stage at Women’s HealthX responds directly to this gap, convening senior decision makers and innovators to explore how sex specific science, digital health, and new care models can reshape outcomes for women.

Attending pharma & healthcare organisations include:

• Tracy Sims, Executive Director, Cardiometabolic Health, Eli Lilly
• Adrian Kielhorn, Senior Director, Global Head HEOR Neurology, Alexion Pharmaceuticals
• Lauren Powell, Head of Health Equity and Clinical Innovation, Biogen
• Amy Kao, SVP, Head of Neuroscience and Immunology Research, EMD Serono
• Stella Vnook, Executive Chair and CEO, Kaida Biopharma
• Amanda Borsky, Director, Clinical Research, Northwell Health
• Lacey McIntosh, Division Chief, Oncologic and Molecular Imaging, UMass Memorial Medical Center
• Nicole Turck, Vice President Operations, Women’s Health, Corewell Health
• Mette Dyhrberg, CEO, Autoimmune Registry
• Lyn Agostinelli, Principal Consultant, Halloran Consulting Group

Sessions addressing the real gaps in women’s chronic care

The agenda features a series of high impact sessions tackling the structural and scientific gaps in women’s health:

• Improving outcomes in obesity through evidence based person centered care: Eli Lilly
• Tackling sex based health inequities by breaking down barriers and bias: Alexion Pharmaceuticals
• Close the health equity gap in women’s health by improving how autoimmune diseases are diagnosed, treated and managed: Autoimmune Registry
• How a GYN only care model is driving faster access to gynecological care: Corewell Health
• Transforming early detection in ovarian cancer: new pathways to accuracy, safety, and better outcomes: UMass Memorial Medical Center

Panel discussions include:

• Why chronic disease looks different in women and why health systems haven’t adapted: Biogen, Kaida Biopharma, EMD Serono
• How can we better engage with our customers: Northwell Health, Halloran Consulting Group

Health equity starts here. REGISTER YOUR PLACE

Why This Matters Now

Women’s HealthX positions chronic disease not just as a clinical challenge, but as a critical frontier for innovation, investment, and system redesign.

From AI powered monitoring and digital therapeutics to real world data and integrated care pathways, the stage highlights where meaningful progress is already being made and where the biggest opportunities lie.

For the FemTech ecosystem, this represents a pivotal moment: aligning technology, clinical insight, and commercial strategy to finally close the long standing data and care gaps in women’s health.

About Women’s HealthX

Women’s HealthX is where the transformation of women’s health begins at its true foundation: data, science, and evidence.

It’s the leading event dedicated to closing the sex difference data gap and accelerating breakthroughs through science driven, real world case studies.

Taking place on December 3 to 4, 2026 in Boston, USA, the exhibition will bring together more than 750 healthcare leaders, including clinicians, payers, employers, investors, and policymakers.

Seven different stages with 150+ expert speakers taking an holistic approach to women’s health. From fertility, maternity, sexual health, cognitive health, menopause and chronic disease, we address care at every stage of a woman’s life.